Approval · Notice of Compliance 32926 · 2024
RUXIENCE: Notice of Compliance 32926
Issued March 6, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32926
- Date
- March 6, 2024
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph update
- Canadian reference product
- RITUXAN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RUXIENCE | Not yet assigned | — |
Medicinal ingredients
- RITUXIMAB 10 MG per ML